Buchang Pharma to cancel repurchased shares, reduce registered capital

Shandong Buchang Pharmaceuticals (SSE:603858) announced its intention to cancel 44,853,573 repurchased shares and reduce its registered capital. This decision follows shareholder approval at the 2024 annual general meeting. The repurchased shares, acquired through concentrated bidding, represent 4.06% of the company’s total share capital at the time of repurchase, with a total expenditure of CNY 712,376,442.81. The company has also repurchased 6,620,630 shares in 2025 at an expenditure of CNY 98,055,757.84. Following the cancellation, the total number of shares will decrease from 1,106,042,645 to 1,054,568,442. Creditors have 45 days from the date of this announcement to claim their rights.